Pertuzumab HER2 inhibitors  

Omnitarg - Perjeta - pertuzumab      

Select             pdf
Trial Studied trt Control trt patientstagsROB Trial resultprogression or death (progression free survival PFS) death (overall survival)

advanced breast cancer (metastatic)  

CLEOPATRA, 2012          NCTpertuzumab + trastuzumab +docetaxeltrastuzumab + docetaxel 1st line HER-2 positive Low risk of bias suggesting-38%-32%
neoSphere (Group B), 2012      NCTpertuzumab + trastuzumab +docetaxeltrastuzumab + docetaxel HER-2 positive Exploratory -

early breast cancer  

Aphinity    NCTpertuzumabplaceboLow risk of bias -